1-19 of 19
Wei Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling

Wei Li, Renata Sano, Mutiah Apatira, Felix DeAnda, Tarikere Gururaja, Muhua Yang, Greta Lundgaard, Chin Pan, Jing Liu, Yongjiao Zhai, Woo Hyun Yoon, Longcheng Wang, Chris Tse, Andrew J. Souers, Chih-Hung Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 35–46.
https://doi.org/10.1158/1535-7163.MCT-22-0642
Published: 03 January 2024
View article titled, Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling
Open the PDF for Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling in another window
Includes: Supplementary data
Journal Articles

Abstract C125: Development of attenuated orf virus as a new generation oncolytic viral vector

Yumiko Yamada, Wei-Li Hsu, Yu-Chih Wang, Hao-Ping Liu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C125.
https://doi.org/10.1158/1535-7163.TARG-23-C125
Published: 01 December 2023
View article titled, Abstract C125: Development of attenuated orf virus as a new generation oncolytic viral vector
Journal Articles

FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma

Peter M. Sullivan, Rajesh Kumar, Wei Li, Virginia Hoglund, Lingyan Wang, Yue Zhang, Megan Shi, Dusan Beak, Adam Cheuk, Michael C. Jensen, Javed Khan, Dimiter S. Dimitrov, Rimas J. Orentas
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (10): 1608–1621.
https://doi.org/10.1158/1535-7163.MCT-22-0059
Published: 07 October 2022
View article titled, FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma
Open the PDF for FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer

Shanshan Deng, Raisa I. Krutilina, Kelli L. Hartman, Hao Chen, Deanna N. Parke, Rui Wang, Foyez Mahmud, Dejian Ma, Pradeep B. Lukka, Bernd Meibohm, Tiffany N. Seagroves, Duane D. Miller, Wei Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (7): 1103–1114.
https://doi.org/10.1158/1535-7163.MCT-21-0899
Published: 05 July 2022
View article titled, Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer
Open the PDF for Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract P108: In vivo CRISPR screens identify E3 ligase COP1 as a modulator of macrophage infiltration and cancer immunotherapy target

Xiaoqing Wang, Collin Tokheim, Shengqing S. Gu, Binbin Wang, Qin Tang, Yihao Li, Nicole Traugh, Zexian Zeng, Yi Zhang, Boning Zhang, Jingxin Fu, Tengfei Xiao, Wei Li, Clifford Meyer, Peng Jiang, Paloma Cejas, Klothilda Lim, Henry Long, Myles Brown, X. Shirley Liu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P108.
https://doi.org/10.1158/1535-7163.TARG-21-P108
Published: 01 December 2021
View article titled, Abstract P108: In vivo CRISPR screens identify E3 ligase COP1 as a modulator of macrophage infiltration and cancer immunotherapy target
Journal Articles

An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance

Shanshan Deng, Raisa I. Krutilina, Qinghui Wang, Zongtao Lin, Deanna N. Parke, Hilaire C. Playa, Hao Chen, Duane D. Miller, Tiffany N. Seagroves, Wei Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (2): 348–363.
https://doi.org/10.1158/1535-7163.MCT-19-0536
Published: 06 February 2020
View article titled, An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance
Open the PDF for An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance in another window
Includes: Supplementary data
Journal Articles

Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor

Guannan Zhao, Qinghui Wang, Zhongzhi Wu, Xinchun Tian, Huan Yan, Baojin Wang, Peixin Dong, Hidemichi Watari, Lawrence M. Pfeffer, Yuqi Guo, Wei Li, Junming Yue
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2233–2245.
https://doi.org/10.1158/1535-7163.MCT-19-0118
Published: 02 December 2019
View article titled, Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor
Open the PDF for Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor in another window
Includes: Supplementary data
Journal Articles

Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer

Tsuyoshi Hata, Hasan Rajabi, Masaaki Yamamoto, Caining Jin, Rehan Ahmad, Yan Zhang, Ling Kui, Wei Li, Yota Yasumizu, Deli Hong, Masaaki Miyo, Masayuki Hiraki, Takahiro Maeda, Yozo Suzuki, Hidekazu Takahashi, Mehmet Samur, Donald Kufe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (10): 1744–1754.
https://doi.org/10.1158/1535-7163.MCT-19-0156
Published: 01 October 2019
View article titled, Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer
Open the PDF for Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Nigericin Exerts Anticancer Effects on Human Colorectal Cancer Cells by Inhibiting Wnt/β-catenin Signaling Pathway

Fei Liu, Wei Li, Shangbo Hua, Ye Han, Zhihua Xu, Daiwei Wan, Yilin Wang, Weichang Chen, Yuting Kuang, Jianming Shi, Qiaoming Zhi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (5): 952–965.
https://doi.org/10.1158/1535-7163.MCT-17-0906
Published: 30 April 2018
View article titled, Nigericin Exerts Anticancer Effects on Human Colorectal Cancer Cells by Inhibiting Wnt/β-catenin Signaling Pathway
Open the PDF for Nigericin Exerts Anticancer Effects on Human Colorectal Cancer Cells by Inhibiting Wnt/β-catenin Signaling Pathway in another window
Journal Articles

Abstract PR06: CRISPR screens identified drivers of endocrine resistance and synthetic lethal vulnerabilities in breast cancer

Tengfei Xiao, Wei Li, Xiaoqing Wang, Han Xu, Qiu Wu, Peng Jiang, Jixin Yang, Teng Fei, Chongzhi Zang, Qi Liao, Jonathan Rennhack, Eran Andrechek, Nanlin Li, Rinath Jeselsohn, Shirley X. Liu, Myles Brown
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (10_Supplement): PR06.
https://doi.org/10.1158/1538-8514.SYNTHLETH-PR06
Published: 02 October 2017
View article titled, Abstract PR06: CRISPR screens identified drivers of endocrine resistance and synthetic lethal vulnerabilities in breast cancer
Journal Articles

A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity

Michael L. Miller, Nathan E. Fishkin, Wei Li, Kathleen R. Whiteman, Yelena Kovtun, Emily E. Reid, Katie E. Archer, Erin K. Maloney, Charlene A. Audette, Michele F. Mayo, Alan Wilhelm, Holly A. Modafferi, Rajeeva Singh, Jan Pinkas, Victor Goldmacher, John M. Lambert, Ravi V.J. Chari
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (8): 1870–1878.
https://doi.org/10.1158/1535-7163.MCT-16-0184
Published: 03 August 2016
View article titled, A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
Open the PDF for A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity in another window
Includes: Supplementary data
Journal Articles

Radioprotection of the Brain White Matter by Mn(III) N-Butoxyethylpyridylporphyrin–Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP5+

Douglas H. Weitzel, Artak Tovmasyan, Kathleen A. Ashcraft, Zrinka Rajic, Tin Weitner, Chunlei Liu, Wei Li, Anne F. Buckley, Mark R. Prasad, Kenneth H. Young, Ramona M. Rodriguiz, William C. Wetsel, Katherine B. Peters, Ivan Spasojevic, James E. Herndon, II, Ines Batinic-Haberle, Mark W. Dewhirst
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (1): 70–79.
https://doi.org/10.1158/1535-7163.MCT-14-0343
Published: 13 January 2015
View article titled, Radioprotection of the Brain White Matter by Mn(III) <em>N</em>-Butoxyethylpyridylporphyrin–Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP<sup>5+</sup>
Open the PDF for Radioprotection of the Brain White Matter by Mn(III) <em>N</em>-Butoxyethylpyridylporphyrin–Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP<sup>5+</sup> in another window
Includes: Supplementary data
Journal Articles

Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma

Jin Wang, Jianjun Chen, Duane D. Miller, Wei Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (1): 16–26.
https://doi.org/10.1158/1535-7163.MCT-13-0212
Published: 13 January 2014
View article titled, Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAF<sup>V600E</sup> Melanoma
Open the PDF for Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAF<sup>V600E</sup> Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.

Kathleen Whiteman, Holly Johnson, Alan Wilhelm, Michael Miller, Wei Li, Emily Reid, Katie Archer, Nathan Fishkin, Andre Dandeneau, Erin Maloney, Jan Pinkas, Ravi Chari
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C162.
https://doi.org/10.1158/1535-7163.TARG-13-C162
Published: 01 November 2013
View article titled, Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.
Journal Articles

Abstract C160: New class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs).

Michael Miller, Nathan Fishkin, Wei Li, Emily Reid, Katie Archer, Erin Maloney, Yelena Kovtun, Gregory Jones, Megan Ellis, Rajeeva Singh, Kathleen Whiteman, Jan Pinkas, Ravi Chari
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C160.
https://doi.org/10.1158/1535-7163.TARG-13-C160
Published: 01 November 2013
View article titled, Abstract C160: New class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs).
Journal Articles

Interaction of the Sympathetic Nerve with Pancreatic Cancer Cells Promotes Perineural Invasion through the Activation of STAT3 Signaling

Kun Guo, Qingyong Ma, Junhui Li, Zheng Wang, Tao Shan, Wei Li, Qinhong Xu, Keping Xie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (3): 264–273.
https://doi.org/10.1158/1535-7163.MCT-12-0809
Published: 10 March 2013
View article titled, Interaction of the Sympathetic Nerve with Pancreatic Cancer Cells Promotes Perineural Invasion through the Activation of STAT3 Signaling
Open the PDF for Interaction of the Sympathetic Nerve with Pancreatic Cancer Cells Promotes Perineural Invasion through the Activation of STAT3 Signaling in another window
Includes: Supplementary data
Journal Articles

Abstract A152: Multiplex assay in FFPE tissues to simulateously quantify the human EGF receptor (HER1–4) family proteins: Implications for targeted therapy and resistance to therapy.

Todd Hembrough, Wei-Li Liao, Sheeno Thyparambil, Joe Abdo, Kathleen Bengali, Marlene Darfler, David Krizman, Jon Burrows
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A152.
https://doi.org/10.1158/1535-7163.TARG-11-A152
Published: 12 November 2011
View article titled, Abstract A152: Multiplex assay in FFPE tissues to simulateously quantify the human EGF receptor (HER1–4) family proteins: Implications for targeted therapy and resistance to therapy.
Journal Articles

Abstract B126: Potent antigen‐specific anti‐tumor activity observed with antibody‐drug conjugates (ADCs) made using a new class of DNA‐crosslinking agents

Michael Miller, Nathan Fishkin, Wei Li, Barbara Leece, Michele Mayo, Gregory Jones, Emily Reid, Katie Archer, Erin Maloney, Yelena Kovtun, Jan Pinkas, Rajeeva Singh, Ravi Chari
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B126.
https://doi.org/10.1158/1535-7163.TARG-09-B126
Published: 10 December 2009
View article titled, Abstract B126: Potent antigen‐specific anti‐tumor activity observed with antibody‐drug conjugates (ADCs) made using a new class of DNA‐crosslinking agents
Journal Articles

The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models

Han Ying, Sandra L. Biroc, Wei-wei Li, Bruno Alicke, Jian-Ai Xuan, Rene Pagila, Yasuhiro Ohashi, Toshiya Okada, Yoichi Kamata, Harald Dinter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (9): 2158–2164.
https://doi.org/10.1158/1535-7163.MCT-05-0440
Published: 19 September 2006
View article titled, The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models
Open the PDF for The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models in another window